The associations of CSF α-synuclein with established biomarkers such as t-tau protein and Aβ40 could somewhat improve the differential diagnosis of Alzheimer’s disease with the primary α-synucleinopathies and better predict longitudinal changes in cognition. This evidence concerns the gene SNCA and Alzheimer disease.